Nutrition in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Abstract
Lifestyle change, including weight loss in children with overweight and obesity, through intensive health behavior and lifestyle treatment (IHBLT) is one of the main pillars in the management of pediatric metabolic dysfunction-associated steatotic liver disease (MASLD). Approximately 10% of school-aged children in the United States-and an even higher percentage of children with obesity-are affected by MASLD. The stigma, combined with peer and society pressure to maintain a "healthy" weight, as it pertains to MASLD, has led a percentage of affected children to adapt restrictive patterns of eating that have culminated in malnutrition, nutrient deficiencies, disordered eating, anxiety and mood, and eating disorders. Prompt recognition through screening and targeted interventions is needed to address this crisis. Our paper offers a concise review and approach to the nutrition evaluation and assessment of malnutrition and nutrition deficiencies in children with pediatric obesity and MASLD and addresses interventions considered to mitigate this health outcome. We reviewed the literature pertaining to pediatric MASLD and malnutrition, nutrient deficiencies, eating behaviors, eating disorders, disordered eating, and food insecurity in the pediatric population. We focused on the evaluation, assessment, and management of malnutrition and nutrition and behavioral interventions recommended in pediatric MASLD. Overall, IHBLT alone has not been sufficient to curb the pediatric obesity and…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.